Neurocrine Biosciences, Inc. (LON:0K6R)
London · Delayed Price · Currency is GBP · Price in USD 141.50
-2.54 (-1.76%)
Dec 30, 2025, 5:00 PM BST
Neurocrine Biosciences Market Cap
Neurocrine Biosciences has a market cap or net worth of 10.43 billion as of December 30, 2025. Its market cap has increased by 2.43% in one year.
Market Cap
10.43B
Enterprise Value
9.96B
Revenue
2.00B
Ranking
n/a
PE Ratio
32.76
Stock Price
141.50
Market Cap Chart
Since May 23, 1996, Neurocrine Biosciences's market cap has increased from 136.97M to 10.43B, an increase of 7,515.50%. That is a compound annual growth rate of 15.75%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Dec 29, 2025 | 10.62B | -3.81% |
| Dec 31, 2024 | 11.04B | 8.62% |
| Dec 29, 2023 | 10.16B | 6.65% |
| Dec 30, 2022 | 9.53B | 59.70% |
| Dec 31, 2021 | 5.97B | -9.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 213.19B |
| GSK plc | 73.15B |
| Haleon | 33.22B |
| Smith & Nephew | 10.37B |
| Convatec Group | 4.64B |
| Hikma Pharmaceuticals | 3.39B |
| Genus | 1.73B |
| HUTCHMED (China) | 1.71B |